ID   PYDC4_HUMAN             Reviewed;          45 AA.
AC   P0DMW2;
DT   27-MAY-2015, integrated into UniProtKB/Swiss-Prot.
DT   27-MAY-2015, sequence version 1.
DT   03-AUG-2022, entry version 34.
DE   RecName: Full=NLR family pyrin domain-containing protein 2B {ECO:0000312|HGNC:HGNC:29887};
DE   AltName: Full=Pyrin domain-containing protein 2-like protein POP4 {ECO:0000305};
DE   AltName: Full=Pyrin-only protein 4 {ECO:0000303|PubMed:24871464};
GN   Name=NLRP2B {ECO:0000312|HGNC:HGNC:29887};
GN   Synonyms=CLRX.1 {ECO:0000303|PubMed:24871464},
GN   NLRP2P {ECO:0000312|HGNC:HGNC:29887}, NOD24 {ECO:0000303|PubMed:24871464},
GN   POP4 {ECO:0000303|PubMed:24871464};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, INDUCTION BY
RP   LPS, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=24871464; DOI=10.1038/gene.2014.30;
RA   Porter K.A., Duffy E.B., Nyland P., Atianand M.K., Sharifi H., Harton J.A.;
RT   "The CLRX.1/NOD24 (NLRP2P) pseudogene codes a functional negative regulator
RT   of NF-kappaB, pyrin-only protein 4.";
RL   Genes Immun. 15:392-403(2014).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
CC   -!- FUNCTION: May function as a negative regulator of NF-kappa-B by
CC       preventing RELA/p65 phosphorylation at 'Ser-536', thereby inhibiting
CC       its transcriptional activity. Through NF-kappa-B regulation may control
CC       cytokine release upon Toll-like receptors activation and therefore play
CC       a role in modulation of innate immunity. May also play a role in cell
CC       cycle progression and apoptotic process. {ECO:0000269|PubMed:24871464}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:24871464}. Nucleus
CC       {ECO:0000269|PubMed:24871464}. Note=Targeted to the nucleus upon TNF-
CC       alpha treatment. {ECO:0000269|PubMed:24871464}.
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues tested, including spleen,
CC       lymph node, thymus, tonsil, peripheral blood leukocyte, bone marrow,
CC       liver, heart, brain, placenta, lung, skeletal muscle, kidney and
CC       pancreas. {ECO:0000269|PubMed:24871464}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal liver.
CC       {ECO:0000269|PubMed:24871464}.
CC   -!- INDUCTION: Up-regulated by inflammatory stimulus (LPS).
CC       {ECO:0000269|PubMed:24871464}.
CC   -!- CAUTION: Likely derived from retrogene insertion of an NLRP2/NLRP7-like
CC       gene, it was originally considered a pseudogene. However, it turns out
CC       to be functional and under purifying selection.
CC       {ECO:0000305|PubMed:24871464}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL807813; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS83476.1; -.
DR   RefSeq; NP_001306896.1; NM_001319967.1.
DR   AlphaFoldDB; P0DMW2; -.
DR   SMR; P0DMW2; -.
DR   BioMuta; NLRP2B; -.
DR   PRIDE; P0DMW2; -.
DR   DNASU; 286430; -.
DR   Ensembl; ENST00000434992.1; ENSP00000488995.1; ENSG00000215174.2.
DR   GeneID; 286430; -.
DR   KEGG; hsa:286430; -.
DR   MANE-Select; ENST00000434992.1; ENSP00000488995.1; NM_001319967.1; NP_001306896.1.
DR   CTD; 286430; -.
DR   GeneCards; NLRP2B; -.
DR   HGNC; HGNC:29887; NLRP2B.
DR   HPA; ENSG00000215174; Not detected.
DR   neXtProt; NX_P0DMW2; -.
DR   OpenTargets; ENSG00000215174; -.
DR   VEuPathDB; HostDB:ENSG00000215174; -.
DR   GeneTree; ENSGT00940000167523; -.
DR   OrthoDB; 1640509at2759; -.
DR   BioGRID-ORCS; 286430; 0 hits in 7 CRISPR screens.
DR   GenomeRNAi; 286430; -.
DR   Pharos; P0DMW2; Tbio.
DR   PRO; PR:P0DMW2; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000215174; Expressed in buccal mucosa cell and 3 other tissues.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0010804; P:negative regulation of tumor necrosis factor-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0050727; P:regulation of inflammatory response; IBA:GO_Central.
DR   Gene3D; 1.10.533.10; -; 1.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   SUPFAM; SSF47986; SSF47986; 1.
PE   2: Evidence at transcript level;
KW   Cytoplasm; Immunity; Innate immunity; Nucleus; Reference proteome;
KW   Signal transduction inhibitor.
FT   CHAIN           1..45
FT                   /note="NLR family pyrin domain-containing protein 2B"
FT                   /id="PRO_0000433153"
SQ   SEQUENCE   45 AA;  4993 MW;  A110C36DF450BD57 CRC64;
     MVSSAQLDFN LQALLGQLSQ DDLCKFKSLI RTVSLGNELQ KIPQT